Free Trial
NASDAQ:XGN

Exagen (XGN) Stock Price, News & Analysis

Exagen logo
$6.96 -0.09 (-1.28%)
As of 04:00 PM Eastern

About Exagen Stock (NASDAQ:XGN)

Key Stats

Today's Range
$6.82
$7.04
50-Day Range
$5.63
$7.73
52-Week Range
$1.75
$7.95
Volume
66,968 shs
Average Volume
136,426 shs
Market Capitalization
$148.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

Exagen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

XGN MarketRank™: 

Exagen scored higher than 59% of companies evaluated by MarketBeat, and ranked 264th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Exagen has only been the subject of 4 research reports in the past 90 days.

  • Read more about Exagen's stock forecast and price target.
  • Earnings Growth

    Earnings for Exagen are expected to grow in the coming year, from ($0.88) to ($0.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Exagen is -8.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Exagen is -8.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Exagen has a P/B Ratio of 12.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Exagen's valuation and earnings.
  • Percentage of Shares Shorted

    1.83% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exagen has recently increased by 15.24%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Exagen does not currently pay a dividend.

  • Dividend Growth

    Exagen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.83% of the float of Exagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Exagen has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Exagen has recently increased by 15.24%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    1 people have searched for XGN on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Exagen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.60% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Exagen's insider trading history.
Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

XGN Stock News Headlines

Exagen Insider Ups Holding During Year
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

XGN Stock Analysis - Frequently Asked Questions

Exagen's stock was trading at $4.10 at the start of the year. Since then, XGN shares have increased by 69.8% and is now trading at $6.96.

Exagen Inc. (NASDAQ:XGN) issued its quarterly earnings results on Monday, May, 12th. The company reported ($0.20) EPS for the quarter, hitting analysts' consensus estimates of ($0.20). The business had revenue of $15.50 million for the quarter, compared to analyst estimates of $14.55 million. Exagen had a negative net margin of 27.34% and a negative trailing twelve-month return on equity of 133.69%.
Read the conference call transcript
.

Exagen (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), Cassava Sciences (SAVA), CNX Resources (CNX) and Ford Motor (F).

Company Calendar

Last Earnings
5/12/2025
Today
7/07/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Healthcare
Current Symbol
NASDAQ:XGN
Fax
N/A
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$8.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+7.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.11 million
Pretax Margin
-27.32%

Debt

Sales & Book Value

Annual Sales
$55.64 million
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
12.89

Miscellaneous

Free Float
18,616,000
Market Cap
$148.25 million
Optionable
Optionable
Beta
1.58
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:XGN) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners